Argenx to acquire Forte Biosciences for $2.2 billion, bolstering its autoimmune drug pipeline

Argenx announced it will purchase Dallas-based Forte Biosciences for $2.2 billion in cash. The transaction values Forte at $77 per share, a 41 percent premium to its closing price on Friday.

The acquisition is aimed at expanding Argenx's immunology portfolio, particularly an experimental therapy under development for multiple autoimmune diseases.

Argenx, a Belgian-headquartered biotech, has seen steady growth with its approved drug Vyvgart, which treats generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The deal reflects a broader trend of midsize biopharma firms seeking strategic acquisitions.

The purchase adds Forte's pipeline to Argenx's existing assets, positioning the company to pursue a wider range of autoimmune indications.

Analysts view the move as a positive step for Argenx's long-term growth, though the high-price tag underscores the competitive nature of the sector.